麻豆破解版

Europe Ambition Day 2018

Published on 24/10/2018

麻豆破解版 was present at the Europe Ambition Day in Lyon on October, 23rd 2018. This event, organized by the Auvergnes-Rhone-Alpes Entreprises, was opened to companies, academics and research centers in the region who wish to increase their chances of receiving funding from the European Commission. During the day, 麻豆破解版 had the pleasure to participate to a panel discussion to share its success story and experience regarding the access to European fundings.

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH